Stock Price Movement and Market Context
On 27 Feb 2026, Dishman Carbogen Amcis Ltd’s shares hit an intraday low of Rs.173.6, representing a 6.16% drop from the previous close. This decline contributed to a day change of -5.43%, underperforming the Pharmaceuticals & Biotechnology sector by over 5%. The stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling sustained downward momentum.
In comparison, the broader market index, Sensex, experienced a decline of 470.94 points (-0.61%) to close at 81,749.54 after opening flat. While some indices such as the S&P Bse Oil Gas reached new 52-week highs, Dishman Carbogen’s performance remained subdued, highlighting sector-specific pressures.
Long-Term Performance and Relative Weakness
Over the past year, Dishman Carbogen Amcis Ltd’s stock has delivered a negative return of -15.03%, contrasting sharply with the Sensex’s positive 9.52% gain over the same period. The stock has also underperformed the BSE500 index across multiple time frames, including the last three years, one year, and three months, indicating persistent challenges in maintaining investor confidence and market relevance.
The 52-week high for the stock was Rs.321.15, underscoring the extent of the recent decline from its peak levels.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Financial Metrics Highlighting Current Concerns
Dishman Carbogen Amcis Ltd’s financial indicators reveal areas of concern that have contributed to the stock’s decline. The company’s Return on Capital Employed (ROCE) stands at a low 0.97%, reflecting weak long-term capital efficiency. Net sales have grown at a modest annual rate of 8.10% over the last five years, which is below industry expectations for robust growth.
Debt servicing capacity is limited, with a high Debt to EBITDA ratio of 4.96 times, indicating elevated leverage and potential strain on cash flows. Quarterly financial results further underscore challenges: the Profit After Tax (PAT) fell by 403.0% to a loss of Rs.12.97 crores, while operating profit to interest coverage ratio dropped to a low 2.47 times. Quarterly PBDIT also declined to Rs.113.11 crores, marking one of the lowest levels in recent periods.
Institutional Investor Sentiment
Institutional investors have reduced their holdings by 0.51% over the previous quarter, now collectively holding 8.93% of the company’s shares. This decline in institutional participation may reflect cautious sentiment among investors with greater analytical resources, potentially signalling concerns about the company’s fundamentals and outlook.
Valuation and Relative Positioning
Despite the challenges, Dishman Carbogen Amcis Ltd’s valuation metrics suggest some degree of market discounting. The company’s ROCE of 3.2 and an enterprise value to capital employed ratio of 0.6 indicate a valuation that is attractive relative to its peers’ historical averages. The stock trades at a discount compared to sector valuations, which may reflect the market’s cautious stance.
Interestingly, while the stock has generated a negative return of -15.03% over the past year, its profits have risen by 233.1%, resulting in a low PEG ratio of 0.1. This divergence between profit growth and share price performance highlights a complex valuation dynamic within the company’s financial profile.
Why settle for Dishman Carbogen Amcis Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Mojo Score and Analyst Ratings
Dishman Carbogen Amcis Ltd currently holds a Mojo Score of 17.0, with a Mojo Grade of Strong Sell as of 12 Jan 2026, an upgrade from the previous Sell rating. The company’s market capitalisation grade is 3, reflecting its small-cap status within the Pharmaceuticals & Biotechnology sector. These ratings encapsulate the overall assessment of the company’s financial health, growth prospects, and market performance.
Summary of Key Performance Indicators
To summarise, the stock’s recent fall to Rs.173.6 represents a culmination of subdued sales growth, elevated leverage, declining profitability, and reduced institutional interest. The stock’s underperformance relative to the Sensex and sector benchmarks over multiple time frames further emphasises the challenges faced by Dishman Carbogen Amcis Ltd in maintaining market confidence.
While valuation metrics suggest the stock is trading at a discount, the financial and market data indicate a cautious environment for the company’s shares at present.
Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today
